NYSE:MANE

Veradermics (MANE) Stock Price, News & Analysis

Veradermics logo
$124.08 -1.56 (-1.24%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Veradermics Stock (NYSE:MANE)

Advanced

Key Stats

Today's Range
$122.58
▼
$127.68
50-Day Range
$98.21
▼
$156.11
52-Week Range
$32.00
▼
$156.63
Volume
122,528 shs
Average Volume
647,126 shs
Market Capitalization
$5.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$174.57
Consensus Rating
Moderate Buy

Company Overview

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use.

VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

AI Generated. May Contain Errors.

Veradermics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

MANE MarketRank™: 
2.993600853215 of 5 stars

Veradermics scored higher than 60% of companies evaluated by MarketBeat, and ranked 353rd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veradermics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Veradermics has a consensus price target of $174.57, representing about 38.8% upside from its current price of $125.76.

  • Amount of Analyst Coverage

    Veradermics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Veradermics' stock forecast and price target.
  • Earnings Growth

    Earnings for Veradermics are expected to decrease in the coming year, from ($2.87) to ($3.03) per share.

  • Price to Book Value per Share Ratio

    Veradermics has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.11% of the float of Veradermics has been sold short.
  • Short Interest Ratio / Days to Cover

    Veradermics has a short interest ratio ("days to cover") of 5.06.
  • Change versus previous month

    Short interest in Veradermics has recently decreased by 8.36%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Veradermics does not currently pay a dividend.

  • Dividend Growth

    Veradermics does not have a long track record of dividend growth.

  • News Sentiment

    Veradermics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Veradermics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 5 people have searched for MANE on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Veradermics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Veradermics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $155,627,500.00 in company stock.

  • Percentage Held by Institutions

    Veradermics has minimal institutional ownership at this time.

  • Read more about Veradermics' insider trading history.
Receive MANE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradermics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MANE Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Veradermics (NYSE:MANE) Stock Gets Price Target Boost from Citigroup
Veradermics (NYSE:MANE) Sets New 52-Week High After Analyst Upgrade
Veradermics: Q3 earnings snapshot
Veradermics (MANE) Stock Price Target 2026
See More Headlines

MANE Stock Analysis - Frequently Asked Questions

Veradermics' stock was trading at $43.46 on February 16, 2026. Since then, MANE stock has increased by 189.4% and is now trading at $125.7640.

Veradermics, Incorporated (NYSE:MANE) released its earnings results on Tuesday, November, 10th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09.

Veradermics (MANE) raised $226 million in an initial public offering (IPO) on Wednesday, February 4th 2026. The company issued 15,077,647 shares at a price of $14.00-$16.00 per share.

Veradermics' top institutional shareholders include State Street Corp (1.52%), Bamco Inc. NY (0.52%), Marshall Wace LLP (0.44%) and Goldman Sachs Group Inc. (0.29%). Insiders that own company stock include Longitude Capital Partners V,, Montanova Capital, Llc, John W Childs, Reid Alexander Waldman and Timothy August Durso.
View institutional ownership trends
.

Shares of MANE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/10/2026
Today
11/18/2026
Jefferies Global Healthcare Conference
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:MANE
CIK
1827635
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

High Price Target
$204.00
Low Price Target
$135.00
Potential Upside/Downside
+40.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-20.50%
Return on Assets
-17.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
77.68
Quick Ratio
77.68

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$18.88 per share
Price / Book
6.57

Miscellaneous

Outstanding Shares
42,190,000
Free Float
N/A
Market Cap
$5.24 billion
Optionable
Optionable
Beta
N/A
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NYSE:MANE) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners